Department of Orthopaedic Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
Department of Bacteriology, Okayama University Graduate School of Medicine, Okayama, Japan.
Spine (Phila Pa 1976). 2017 Sep 1;42(17):E995-E1001. doi: 10.1097/BRS.0000000000002074.
An experimental study.
To evaluate the effectiveness of freeze-dried bone allograft (FDBA) with basic fibroblast growth factor (bFGF) fused with the polycystic kidney disease domain (PKD) and the collagen-binding domain (CBD) of Clostridium histolyticum collagenase, for the acceleration of lumbar posterolateral fusion in rats.
Reports indicate bFGF is an effective growth factor with osteogenic potential for promoting bone regeneration, although its efficiency decreases rapidly following its diffusion in body fluid from the host site. We developed a bFGF fusion protein containing the PKD and the CBD of C histolyticum collagenase (bFGF-PKD-CBD), which markedly enhanced bone formation at a relatively low concentration when applied to the surface of rat femurs in a previous study. The potential of this novel protein to accelerate bone fusion in a rat model of lumbar posterolateral fusion has yet to be investigated.
Bilateral L4-L5 posterolateral fusions were performed, using 150 mg of FDBA powder per side. A total of 20 male Sprague-Dawley rats weighing 200 to 250 g/each were divided into two groups of 10 rats: FDBA was incubated with either phosphate-buffered saline (control group) or 0.58 nmol bFGF-PKD-CBD (bFGF-PKD-CBD group) before fusion surgery. The effect of bFGF-PKD-CBD was estimated using radiographs, microcomputed tomography, and histology (hematoxylin-eosin and von Kossa staining).
Both grafted bone volume in the posterolateral lesion and the volume of new bone formation on the surface of laminae and spinal processes were significantly higher in the bFGF-PKD-CBD group than in the control group. Histologically, new bone formation and surrounding chondrocytes and fibroblasts were prominent in the bFGF-PKD-CBD group.
FDBA infused with bFGF-PKD-CBD may be a promising material for accelerating spinal fusion, and the FDBA-based delivery system for localizing bFGF-PKD-CBD may offer novel therapeutic approaches to augment spinal fusion.
N/A.
实验研究。
评估与碱性成纤维细胞生长因子（bFGF）融合的冻干骨移植物（FDBA）的有效性，该融合物融合了多囊肾病域（PKD）和梭菌胶原酶的胶原结合域（CBD），用于加速大鼠腰椎后路融合。
报告表明，bFGF 是一种有效的具有成骨潜力的生长因子，可促进骨再生，尽管其在从宿主部位扩散到体液中后效率会迅速降低。我们开发了一种含有 C 组梭菌胶原酶的 PKD 和 CBD 的 bFGF 融合蛋白（bFGF-PKD-CBD），在之前的一项研究中，当将其应用于大鼠股骨表面时，该融合蛋白在相对较低的浓度下显著增强了骨形成。这种新型蛋白在大鼠腰椎后路融合模型中加速骨融合的潜力尚未得到研究。
双侧 L4-L5 后路融合术，每侧使用 150mg FDBA 粉末。共 20 只 200-250g/只的雄性 Sprague-Dawley 大鼠分为两组，每组 10 只：FDBA 在融合手术前分别与磷酸盐缓冲液（对照组）或 0.58nmol bFGF-PKD-CBD（bFGF-PKD-CBD 组）孵育。使用 X 线片、微计算机断层扫描和组织学（苏木精-伊红和 von Kossa 染色）评估 bFGF-PKD-CBD 的效果。
bFGF-PKD-CBD 组的后外侧病变中移植骨的体积和椎板及棘突表面新骨形成的体积均明显高于对照组。组织学上，bFGF-PKD-CBD 组新骨形成和周围软骨细胞和成纤维细胞明显。
bFGF-PKD-CBD 浸润 FDBA 可能是加速脊柱融合的一种有前途的材料，基于 FDBA 的局部 bFGF-PKD-CBD 的递药系统可能为增强脊柱融合提供新的治疗方法。
N/A。
